Document is current
Any future updates will be listed below
-
Authors
Niu, Lili https://orcid.org/0000-0003-4571-4368
Thiele, Maja https://orcid.org/0000-0003-1854-1924
Geyer, Philipp E.
Rasmussen, Ditlev Nytoft
Webel, Henry Emanuel
Santos, Alberto
Gupta, Rajat
Meier, Florian https://orcid.org/0000-0003-4729-175X
Strauss, Maximilian https://orcid.org/0000-0003-3320-6833
Kjaergaard, Maria https://orcid.org/0000-0001-8452-1820
Lindvig, Katrine
Jacobsen, Suganya
Rasmussen, Simon https://orcid.org/0000-0001-6323-9041
Hansen, Torben https://orcid.org/0000-0001-8748-3831
Krag, Aleksander https://orcid.org/0000-0002-9598-4932
Mann, Matthias https://orcid.org/0000-0003-1292-4799
-
Funding
Funding for this research was provided by:
Max-Planck-Gesellschaft
Novo Nordisk Fonden (NNF15CC0001, NNF15OC0016692, NNF15CC0001, NNF16CC0020906, NNF15OC0016692, NNF14CC0001, NNF15OC0016692, NNF15OC0016692, NNF15OC0016692, NNF14CC0001, NNF19SA0035440, NNF15CC0001, NNF15CC0001, NNF14CC0001)
EC | Horizon 2020 Framework Programme (668031, 668031, 668031, 668031, 668031, 668031, 668031)
- License Information
-
More Information
Article History
Received: 23 March 2021
Accepted: 28 April 2022
First Online: 2 June 2022
Competing interests
: P.E.G. is a cofounder of OmicEra Diagnostics, a company offering MS-based proteomics analysis, the founding of which was during conduction of the study. M.S. is a former employee at OmicEra Diagnostics. M.M. is currently an indirect investor in Evosep. M.T. has a speaker's fee received from Echosens and Siemens Healthcare. A.K. has served as a speaker for Norgine, Siemens and Nordic Bioscience and has participated in advisory boards for Norgine and Siemens, all outside the submitted work. The remaining authors declare no competing interests.
